



May 11, 2026

To,
Listing/ Compliance Department
BSE LTD.
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

SCRIP CODE: 543748

To,
Listing/ Compliance Department
National Stock Exchange of India Limited
“Exchange Plaza”, Plot No. C/1,
G Block, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

SYMBOL: AARTIPHARM

Dear Sir/Madam,

Sub: Intimation of Board Meeting
Ref: Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

In terms of Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations, 2015”), it is hereby intimated that a meeting of the Board of Directors of the Company is scheduled to be held on Monday, May 18, 2026 to inter-alia, consider & approve the following:

1. Audited Financial Results of the Company for the quarter and financial year ended March 31, 2026 after these results are reviewed by the Audit Committee of the Board.
2. Consider and recommend Final Dividend, if any, for the financial year ended March 31, 2026.

Further, in terms of Code for Prevention of Insider Trading in the Securities of the Company, the Trading Window for transactions in the securities of the Company which was closed from April 01, 2026, shall remain closed until May 20, 2026 for the purpose of announcement of aforesaid results.

Please take the same on your records.

Thanking you,

Yours faithfully,
For AARTI PHARMALABS LIMITED

JEEVAN MONDKAR
COMPANY SECRETARY AND LEGAL HEAD
ICSI M. NO. A22565

AARTI PHARMALABS LIMITED

www.aartipharmalabs.com | CIN : L24100GJ2019PLC110964 | Email : info@aartipharmalabs.com

Admin Office : 204, Udyog Kshetra, 2nd Floor, Mulund - Goregaon Link Road, Mulund (W), Mumbai, PIN - 400 080, Maharashtra, INDIA, T : +91 22 67976666 | F : +91 22 25653234
Regd. Office : Plot No. 22-C/1 & 22-C/2, 1st Phase, G.I.D.C., Vapi 396 195, District - Valsad, Gujarat, INDIA, T : +91 260 2400467, +91 99099 94655